Topline data from Embolden™ registrational trial anticipated in 2H 2027 Presented new preclinical data highlighting the purposeful design of NGN-401 for Rett syndrome, including rapid onset and durable expression of full-length MECP2 transgene with single-stranded AAV construct NGN-401 at the 1E15
NEW YORK --(BUSINESS WIRE)--Nov. 5, 2026-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors
NEW YORK --(BUSINESS WIRE)--Nov. 3, 2026-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences:
New data showing rapid and durable full-length MECP2 expression in vivo with single-stranded AAV support improvements observed in NGN-401 Phase 1/2 trial New in vivo data demonstrate that miRNA-based auto-regulatory technology is not responsive to endogenous MeCP2 levels on a cell-by-cell basis
New presentations to highlight rapid transgene expression of full-length MECP2 following single-stranded AAV delivery and evaluation of miRNA-based approaches to regulating MeCP2 expression on a cell-by-cell basis NEW YORK --(BUSINESS WIRE)--Oct. 20, 2026-- Neurogene Inc.
NEW YORK --(BUSINESS WIRE)--Oct. 5, 2026-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors
NEW YORK --(BUSINESS WIRE)--Sep. 8, 2026-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C.
NEW YORK --(BUSINESS WIRE)--Sep. 4, 2026-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors
Data from Phase 1/2 trial of NGN-401 for Rett syndrome showed 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participant; no plateau and no milestone loss observed as of data cutoff date of June 16, 2026 Milestones gained in
NEW YORK --(BUSINESS WIRE)--Aug. 4, 2026-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors
